drugset / Trial / NCT04053543

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.

Timeline

Start
2019-08-09
Primary completion
2020-08-12
Completion
2020-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CXA-10 Small molecule 150 mg